139 related articles for article (PubMed ID: 10947559)
1. A new way to attack cancer.
Stipp D
Fortune; 2000 May; 141(11):164-6, 168, 172 passim. PubMed ID: 10947559
[No Abstract] [Full Text] [Related]
2. Can a rational design for metronomic chemotherapy dosing be devised?
Maraveyas A; Lam T; Hetherington JW; Greenman J
Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
[No Abstract] [Full Text] [Related]
3. Metronomic chemotherapy: teaching old drugs new tricks?
Vogelzang N
Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
[No Abstract] [Full Text] [Related]
4. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic metronomic chemotherapy.
Sarmiento R; Gasparini G
Onkologie; 2008 Apr; 31(4):161-2. PubMed ID: 18418015
[No Abstract] [Full Text] [Related]
6. Cancer research. Obstacle for promising cancer therapy.
Marx J
Science; 2002 Feb; 295(5559):1444. PubMed ID: 11859164
[No Abstract] [Full Text] [Related]
7. Angiogenesis. A boost for tumor starvation.
Marx J
Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
[No Abstract] [Full Text] [Related]
8. Integrins as target: first phase III trial launches, but questions remain.
Carter A
J Natl Cancer Inst; 2010 May; 102(10):675-7. PubMed ID: 20460633
[No Abstract] [Full Text] [Related]
9. [Metronomic chemotherapy in 2011: update and perspectives].
Benbrahim Z; Massard C; El Mesbahi O
Bull Cancer; 2011 Dec; 98(12):1447-54. PubMed ID: 22146261
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Kerbel RS
Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
[TBL] [Abstract][Full Text] [Related]
11. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.
Ledzewicz U; Schättler H
J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982
[TBL] [Abstract][Full Text] [Related]
12. Metronomic dosing of chemotherapy: applications in pediatric oncology.
Stempak D; Seely D; Baruchel S
Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis research: guidelines for translation to clinical application.
Folkman J; Browder T; Palmblad J
Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis as a therapeutic target.
Ferrara N; Kerbel RS
Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
Wright JJ; Zerivitz K; Gravell A
Oncology (Williston Park); 2005 Apr; 19(4):499-502. PubMed ID: 15934518
[No Abstract] [Full Text] [Related]
16. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells.
Bertolini F
Cancer Metastasis Rev; 2008 Mar; 27(1):95-101. PubMed ID: 18066648
[TBL] [Abstract][Full Text] [Related]
17. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
18. [Segidrin: a new-type antineoplastic agent].
Filov VA
Vopr Onkol; 1994; 40(1-3):3-14. PubMed ID: 7701790
[No Abstract] [Full Text] [Related]
19. Antitumor interaction of short course endostatin and ionizing radiation.
Greenberger JS
Cancer J; 2000; 6(5):279-81. PubMed ID: 11079164
[No Abstract] [Full Text] [Related]
20. Inhibition of angiogenesis in the treatment of tumors.
Ostrowski K; Kinsner A
Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
